Insmed, Inc. $INSM Stake Lifted by NWI Management LP

Key Points

• NWI Management LP increased its stake in Insmed, Inc. by 61.3% in Q1, now holding 450,000 shares valued at approximately $34.33 million, making it their 6th largest investment.
• Insmed reported a loss of ($1.70) earnings per share for the last quarter, missing estimates, but achieved a revenue of $107.42 million, surpassing expectations.
• Several analysts have raised their target prices for Insmed, with Morgan Stanley increasing its target from $126 to $144 and maintaining an "equal weight" rating.

NWI Management LP increased its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 61.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 450,000 shares of the biopharmaceutical company's stock after purchasing an additional 171,000 shares during the period. Insmed accounts for 4.3% of NWI Management LP's investment portfolio, making the stock its 6th largest holding. NWI Management LP owned 0.25% of Insmed worth $34,330,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Teachers Retirement System of The State of Kentucky acquired a new stake in Insmed during the 1st quarter worth $975,000. OneDigital Investment Advisors LLC increased its stake in Insmed by 47.1% in the 1st quarter. OneDigital Investment Advisors LLC now owns 5,226 shares of the biopharmaceutical company's stock valued at $399,000 after buying an additional 1,673 shares during the period. Sowell Financial Services LLC acquired a new position in Insmed in the 1st quarter valued at $255,000. GAMMA Investing LLC increased its stake in Insmed by 62.0% in the 1st quarter. GAMMA Investing LLC now owns 1,009 shares of the biopharmaceutical company's stock valued at $77,000 after buying an additional 386 shares during the period. Finally, Paradigm Biocapital Advisors LP acquired a new position in Insmed in the 1st quarter valued at $34,434,000.

Insiders Place Their Bets

In other news, CFO Sara Bonstein sold 58,400 shares of the stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total value of $5,995,928.00. Following the completion of the transaction, the chief financial officer owned 73,505 shares in the company, valued at $7,546,758.35. This trade represents a 44.27% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $93.42, for a total transaction of $9,264,648.24. Following the completion of the transaction, the insider owned 89,407 shares of the company's stock, valued at $8,352,401.94. This represents a 52.59% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 535,320 shares of company stock worth $54,581,793. Insiders own 3.00% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on INSM shares. The Goldman Sachs Group boosted their price objective on shares of Insmed from $114.00 to $142.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. Jefferies Financial Group boosted their price objective on shares of Insmed from $129.00 to $148.00 and gave the company a "buy" rating in a research note on Wednesday, August 13th. Mizuho boosted their price objective on shares of Insmed from $130.00 to $165.00 and gave the company an "outperform" rating in a research note on Wednesday, August 13th. JPMorgan Chase & Co. boosted their price objective on shares of Insmed from $111.00 to $135.00 and gave the company an "overweight" rating in a research note on Wednesday, August 20th. Finally, Morgan Stanley boosted their price objective on shares of Insmed from $126.00 to $144.00 and gave the company an "equal weight" rating in a research note on Thursday, August 21st. Sixteen investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, Insmed currently has a consensus rating of "Moderate Buy" and an average target price of $134.79.

Insmed Price Performance

Shares of INSM traded up $2.57 during trading hours on Friday, reaching $145.10. The company had a trading volume of 2,532,328 shares, compared to its average volume of 2,879,069. The firm has a 50 day simple moving average of $114.64 and a 200-day simple moving average of $89.74. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $30.67 billion, a price-to-earnings ratio of -25.41 and a beta of 0.96. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $146.84.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The company had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business's revenue for the quarter was up 18.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. Research analysts expect that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.